New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
10:01 EDTVMED, RCII, WLP, SGEN, RAX, KOS, DELL, RKUS, MDP, IT, CLWR, RXN, HNZ, FOSL, RATE, SAPE, PIKE, NSP, CLFOn the Fly: Analyst Downgrade Summary
Today’s noteworthy downgrades include: Bankrate (RATE) downgraded to Neutral from Buy at Citigroup... Clearwire (CLWR) downgraded to Underperform from Market Perform at Raymond James... Cliffs Natural (CLF) downgraded to Hold from Buy at Deutsche Bank... Fossil (FOSL) downgraded to Underperform from Market Perform at FBR Capital... Gartner (IT) downgraded to Equal Weight from Overweight at Barclays... Heinz (HNZ) downgraded to Neutral from Buy at UBS... Insperity (NSP) downgraded to Neutral from Buy at SunTrust... Meredith (MDP) downgraded to Neutral from Buy at Roth Capital... Pike Electric (PIKE) downgraded to Neutral from Buy at Janney Capital... Rexnord (RXN) downgraded to Equal Weight from Overweight at Barclays... Ruckus Wireless (RKUS) downgraded to Hold from Buy at Needham... Sapient (SAPE) downgraded to Equal Weight from Overweight at First Analysis... Fossil (FOSL) downgraded to Outperform from Buy at CLSA... Wellpoint (WLP) downgraded to Neutral from Buy at Monness Crespi... Dell (DELL) downgraded to Hold from Buy at Maxim... Kosmos (KOS) downgraded to Accumulate from Buy at Global Hunter... Rent-A-Center (RCII) downgraded to Hold from Buy at Stifel Nicolaus... Rackspace (RAX) downgraded to Hold from Buy at Stifel Nicolaus... Seattle Genetics (SGEN) downgraded to Hold from Buy at Needham... Virgin Media (VMED) downgraded to Equal Weight from Overweight at Evercore.
News For RATE;CLWR;CLF;FOSL;IT;NSP;HNZ;MDP;PIKE;RXN;RKUS;SAPE;WLP;DELL;RAX;RCII;KOS;SGEN;VMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 15, 2014
16:07 EDTRXNRexnord initiated with a Buy at KeyBanc
Subscribe for More Information
10:10 EDTKOSHigh option volume stocks:
High option volume stocks: RVBD AGCO FRO CRUS UBNT LH PAY PETM OREX KOS
07:40 EDTWLPExpress Scripts price target raised to $96 from $82 at UBS
Subscribe for More Information
December 12, 2014
10:01 EDTRAXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BreitBurn Energy (BBEP) downgraded to Hold from Buy at Wunderlich... CIBC (CM) downgraded to Underperform from Neutral at Credit Suisse... Costco (COST) downgraded to Neutral from Buy at Janney Capital... Discovery (DISCA) downgraded to Sector Perform from Outperform at RBC Capital... Emerald Oil (EOX) downgraded to Neutral from Accumulate at Global Hunter... Goodrich Petroleum (GDP) cut to Underweight on lower oil at JPMorgan... Hain Celestial (HAIN) downgraded to Sector Perform from Outperform at RBC Capital... Hovnanian (HOV) downgraded to Neutral from Buy at Compass Point... Mindray Medical (MR) downgraded to Underweight from Equal Weight at Morgan Stanley... Morgan Stanley (MS) downgraded to Neutral from Buy at Buckingham... Oracle (ORCL) resumed with a Neutral from Overweight at Piper Jaffray... Rackspace (RAX) downgraded to Underperform from Neutral at DA Davidson... Zayo Group (ZAYO) downgraded to Neutral from Buy at BTIG.
08:10 EDTRAXRackspace downgraded to Underperform from Neutral at DA Davidson
Subscribe for More Information
December 11, 2014
16:12 EDTRCIIRent-A-Center raises quarterly dividend by 1c to 24c per share
Subscribe for More Information
14:55 EDTRAXRackspace management to meet with William Blair
Subscribe for More Information
09:01 EDTRKUSRuckus Wireless looks attractive into 2015, says Pacific Crest
Subscribe for More Information
07:34 EDTRAXBarclays to hold a bus tour
Subscribe for More Information
06:11 EDTRXNJanus Capital reports 10.6% passive stake in Rexnord
Subscribe for More Information
December 10, 2014
14:45 EDTWLPDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
December 9, 2014
08:52 EDTSAPEPublicis extends tender offer to acquire Sapient
Publicis Groupe S.A. (PUBGY) announced that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Sapient (SAPE) for $25.00 per share in cash. The Offer will now expire at the end of the day, immediately after 11:59 p.m., New York City time, on December 23, unless it is further extended. All other terms and conditions of the Offer remain unchanged.
08:23 EDTPIKEPike Corp. announces ISS recommends holders vote FOR proposed sale transaction
Pike Corporation announced that Institutional Shareholder Services, or ISS, an independent proxy voting and corporate governance advisory firm, has recommended that the company's shareholders vote "FOR" the proposed sale transaction for $12.00 per share in cash.
December 8, 2014
19:42 EDTSGENSeattle Genetics says Adcetris 'demonstrates antitumor activity'
Seattle Genetics highlighted two separate Adcetris data presentations in relapsed/refractory and frontline diffuse large B-cell lymphoma, or DLBCL, at the 56th American Society of Hematology, or ASH, Annual Meeting and Exposition. Adcetris is an antibody-drug conjugate directed to CD30, which is expressed in classical Hodgkin lymphoma, anaplastic large cell lymphoma and several other types of non-Hodgkin lymphoma. Seattle Genetics CEO Clay Siegall said, “The updated phase 2 data at ASH demonstrate encouraging activity of Adcetris in relapsed/refractory DLBCL, even when CD30 is undetectable by standard immunohistochemistry methods. In addition, our data show that Adcetris can be safely combined with RCHOP in the frontline setting with a strong complete remission rate in high-intermediate and high-risk patients. The activity observed supports our plans to initiate a randomized phase 2 clinical trial of Adcetris for relapsed CD30-positive DLBCL patients during 2015 and to pursue possible frontline DLBCL combination trials."
19:41 EDTSGENSeattle Genetics says planning phase 1b combination trial for SGN-CD33A
Subscribe for More Information
10:04 EDTSGENSeattle Genetics highlights 'encouraging' long-term outcomes in Phase 1 trial
Seattle Genetics highlighted multiple ADCETRIS data presentations in frontline and salvage Hodgkin lymphoma at the 56th American Society of Hematology Annual Meeting and Exposition taking place in San Francisco, CA, December 6-9. ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma, a type of T-cell lymphoma. Data highlighted in oral sessions include encouraging long-term outcomes from a phase 1 trial evaluating ADCETRIS in combination with AVD chemotherapy in frontline HL, as well as strong activity evaluating ADCETRIS combination therapy in second-line HL and ADCETRIS monotherapy or combination therapy in frontline HL patients age 60 and older. In addition, encouraging data from multiple investigator-sponsored trials were featured in oral and poster sessions evaluating ADCETRIS in frontline and salvage HL and in non-Hodgkin lymphoma settings.
08:33 EDTSGENSeattle Genetics should be bought on weakness, says RBC Capital
RBC Capital believes that Seattle Genetics' shares could be under pressure today due to questions around its AETHERA data and the checkpoint inhibitor efficacy of its ADCETRIS drug. However, the firm says that other issues are more important over the longer term, including the efficacy of ADCs as a cancer treatment, the emergence of other pipeline products and therapeutic approaches, and efficient development pathways to the market. The firm keeps a $48 price target and Outperform rating on Seattle Genetics.
December 7, 2014
13:23 EDTSGENSeattle Genetics, Takeda announce four-year data from ADCETRIS trial
Subscribe for More Information
12:50 EDTSGENSeattle Genetics presents data from SGN-CD19A antibody-drug conjugate
Subscribe for More Information
12:44 EDTSGENSeattle Genetics, Takeda report Phase 3 AETHERA trial data from Adcetris
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use